Childhood acute myeloid leukemia (AML) is a hematological malignancy in which tumor burden is continuously replenished by leukemic-initiating cells (ICs), which proliferate slowly and are refractory to chemotherapeutic agents. We investigated whether interleukin (IL)-12, an immuno-modulatory cytokine with anti-tumor activity, may target AML blasts (CD45 þ CD33 þ ) and populations known to contain leukemia ICs (that is, CD34 þ CD38 À , CD33 þ CD38 þ and CD44 þ CD38 À cells). We demonstrate for the first time that: i) AML blasts and their
express the heterodimeric IL-12 receptor (IL-12R), ii) AML cells injected subcutaneously into NOD/SCID/Il2rg
À/À (NSG) mice developed a localized tumor mass containing leukemic ICs and blasts that were virtually eliminated by IL-12 treatment, iii) AML cells injected intravenously into NSG mice engrafted within the first month in the spleen, but not in bone marrow or peripheral blood. At this time, IL-12 dramatically dampened AML CD45 þ CD33 þ , CD34 þ CD38
Introduction
Acute myeloid leukemia (AML) is a hematological tumor deriving from malignant transformation of blasts of myeloid origin that proliferate and accumulate in the bone marrow (BM). 1,2 AML is a clinically and genetically heterogeneous disease accounting for more than half of fatal cases in all pediatric leukemia patients. 3, 4 AML-initiating cells (ICs) are functionally defined as human cells that initiate serially transplantable leukemia in severely immunodeficient mice. AML-ICs possess self-renewal ability and maintain the bulk population of leukemia cells. 5, 6 AML-ICs are quiescent, slowly dividing cells that home in BM niches where they find favorable microenvironmental conditions to maintain stemness, to remain dormant over years and to resist to chemotherapeutic agents. [7] [8] [9] Moreover, it has been recently proposed that bulk tumors display a phenotypic plasticity between tumor ICs and non-ICs, and that a dynamic equilibrium may exist between these two populations within a given tumor. 10 Different microenvironmental stimuli may shift such equilibrium in either direction. 10 Thus, based upon this background, ideal therapeutic protocols against AML should incorporate agents that target both ICs and blasts, and exert anti-angiogenic functions affecting the vascular niche of leukemia ICs. 9, 11 Initial analyses on AML cells selected on the basis of cell-surface marker expression, demonstrated that ICs were CD34 þ CD38 À ; in contrast, the CD34 þ CD38 þ and CD34 À fractions contained no cells with these properties. 6, 7, 12, 13 However, more recent studies point to the need for a revised immunophenotypic definition of AML-ICs. Indeed, anti-CD38 antibodies (Abs) were found to exert profound inhibitory effects on engraftment of primary AML cells in NOD/SCID mice and in the more severely immunodeficient NOD/SCID/Il2rg À/À (NSG) mice.
14 Likewise, as CD44 and CD123 surface markers are expressed in AML-ICs, targeting these molecules eliminates AML-ICs and, consequently, the leukemia burden in SCID/NOD mice. 15, 16 Quite recently, Sarry et al. 17 demonstrated that AML-ICs are heterogeneous, may be contained in the CD38 þ AML sub-population, and are not necessarily derived from hematopoietic stem cells, as initially hypothesized.
We have investigated the ability of interleukin (IL)-12 to function as anti-tumor agent against AML blasts and different AML populations containing cells with ICs properties, and to inhibit the angiogenic activity of AML cells. In this connection, we and others have demonstrated that IL-12, which binds to a heterodimeric receptor (R) composed of b1 and b2 chains, [18] [19] [20] inhibits the growth of both solid and hematologic malignancies (that is, multiple myeloma) either by acting directly on tumor cells or through indirect mechanisms, such as induction of anti-tumor natural killer and cytotoxic T lymphocyte responses or inhibition of angiogenesis. [21] [22] [23] [24] Patients and methods
Patients
The Institutional Review Board of Pediatric Hematology and Oncology Division at IRCCS Fondazione Policlinico San Matteo, Pavia, Italy, approved the design of the study. This investigation conformed with the principles of the Declaration of Helsinki. The initial diagnosis of AML together with its subtype was established according to the WHO (World Health Organization) and the French-American-British classification. 25 A total of 20 children with AML were enrolled consecutively, 14 of whom were males and 6 females. At the time of blasts collection, all patients were untreated. Patient age ranged from 3 months to 19 years. Six patients had M2, four M5, four M3, three M4, two M6 and one M1 AML. Clinical characteristics of the children enrolled in the study are detailed in Table 1 . Aliquots of patient BM aspirates performed for diagnostic purposes were obtained after written informed consent at diagnosis and contained at least 85% neoplastic cells. Aliquots of BM aspirates performed for diagnostic purposes from six age-matched individuals not affected by oncologic disorders were obtained following informed consent. Mononuclear cells were isolated from BM by Ficoll-Hypaque density gradient (Sigma Chemical Co., St. Louis, MO, USA), and cells were collected and cryopreserved for later use.
Antibodies, reagents and flow cytometry
The following Abs were used for flow cytometric analyses: PE-conjugated anti-human IL-12Rb1; goat IgG anti-human IL-12Rb2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA); PE-, FITC-, Allophycocyanin (APC)-or tricolor (TC)-conjugated anti-human CD45 (Caltag, Burlingame, CA, USA); FITC-or PE-anti-human CD33 (Caltag); FITC-or PE-or TC-conjugated anti-human CD34 (Caltag); PE-, FITC-, APC-or TC-conjugated anti-human CD38 (Caltag); APC-or FITC-conjugated antihuman CD44, FITC-conjugated anti-human Ki67 (DAKO, Glostrup, Denmark). All of the above monoclonal (m)Abs reacted only with human cells. The anti-human IL-12Rb2 goat IgG detects an intracellular epitope of IL-12Rb2, thus, it was tested using BD Cytofix/Cytoperm fixation/permeabilization kit (BD Biosciences, Franklin Lakes, NJ, USA). Either isotypematched Ab of irrelevant specificity or non-immune goat IgG (Caltag) were used as controls. Cells were scored by Gallios flow cytometry and data were processed using Kaluza 1.1 software (Beckman Coulter, Brea, CA, USA). Data were expressed as percentage of positive cells or mean relative of fluorescence intensity (MRFI), calculated as follows: fluorescence intensity obtained with specific mAb/fluorescence intensity obtained with irrelevant isotype-matched mAb.
hrIL-12, kindly donated by Wyeth (Cambridge, MA, USA), was used for in vivo and in vitro studies.
Transplantation of AML cells in NSG mice
Five/six-week-old NSG mice (Jackson Laboratory, Bar Harbor, ME, USA) were housed under specific pathogen-free conditions. All procedures involving animals were performed in accordance with national and international current regulations (D.L 27/01/ 1992, n.116, European Economic Community Council Directive 86/609, OJL 358, December 1, 1987) . A total of 8 Â 10 6 AML cells from patient (Pt) #16 were injected subcutaneously (s.c.) in two groups of four animals each. One group of mice was treated s.c. with two doses per week of hrIL-12 (1 mg/mouse/dose) starting from 3 days after tumor cell injection. The other group of animals was treated with phosphate-buffered saline (PBS; controls) according to the same time schedule.
In another set of experiments, 10 NSG mice were injected intravenously (i.v.) with 3-5 Â 10 6 AML cell suspensions (from Pt #4, #5, #6, #11, #17, # 18, # 19, or # 20). These samples were selected as they were highly enriched (495%) with neoplastic cells, most of which expressed IL-12Rb2 (at least 82% IL-12Rb2 þ CD33 þ cells). Mice were divided in two groups of five animals each that received i.v. hrIL-12 or PBS according to the same schedule indicated above. Mice were killed when signs of poor health became evident. The following tissues were collected from each animal: spleen, peripheral blood (PB) from the retro-orbital vein, and BM obtained by femur flushing. An engraftment criterion of more than 1% of human CD45 þ cells in mononuclear cells from murine tissues assessed by flow cytometry was used as biologically significant cutoff.
Serial transplantations of human cells isolated by immunomagnetic beads coated with anti-human CD45 mAb (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) from the spleen of control mice were performed. CD45 þ cells from primary and secondary recipients were subjected to molecular analysis of selected polymorphic short tandem repeat loci, as described 26, 27 In some experiments, CD38 þ cells were isolated by immunomagnetic beads coated with anti-human CD38 mAb (Miltenyi Biotec GmbH) from spleen and BM of two PBS-and two IL-12-treated mice, and injected into secondary recipients (7-9 Â 10 5 cells/each animal).
Morphologic and immunohistochemical analyses
Tumor masses explanted from animals injected with primary AML cells were subjected to morphological and immunohistochemical analyses, as described. 28, 29 Briefly, DNA fragmentation associated with apoptosis was detected by terminal deoxynucleotidyl transferase dUTP nick end labeling staining with the ApopTag Plus Peroxidase In Situ Apoptosis Kit (Millipore, Billerica, MA, USA) according to the manufacturer's protocol. Paraffin-embedded sections were immunostained with anti-human IL-6 (Abcam, Cambridge, UK) or anti-human CD44 (AbD Serotec, Oxford, UK) or rat anti-mouse CD31 (clone SZ31; Dianova, Hamburg, Germany).
Real-Time PCR
Total RNA was extracted from two AML samples (Pt #6 and #9) at diagnosis, and from CD45 þ cells isolated from three BM of PBS-treated mice and two from hrIL-12-treated mice injected with the same samples, using the RNeasy micro kit (QIAGEN, GmbH, Hilden, Germany). In all, 1 mg RNA was reverse transcribed using the RevertAid First Strand cDNA Synthesis kit (Fermentas, Thermo Fisher Scientific, MA, USA) and subjected to real-time PCR using the ABI PRISM 7700 Sequence Detector from Applied Biosystems (Carlsbad, CA, USA). Amplification was performed using the IL-12Rb2 and GAPDH primer sets and RT 2 qPCR Master Mix (SABiosciences, Frederick, MD, USA) following manufacturer's instructions. Relative quantification of the IL-12Rb2 transcript was performed using the 2 À(DDCt) method, using normal B cells as calibrator.
Statistical analysis
Differences in the number of vessels formed in CAM assay (see Supplementary Methods), and differences in percentage and absolute numbers were evaluated by Student's t test with 99% confidence interval (GraphPad Prism 3, GraphPad Software, La Jolla, CA, USA). All statistical tests were two tailed. A P-value lower than 0.05 was considered to be statistically significant.
Results

Expression of IL-12R in pediatric AML blasts and
populations from AML patients and healthy donors 
À subsets in which cells with leukemic ICs are contained. 5, 7, 12, 17 These experiments, performed on cell samples from Pt #5, #6, #7, #12 and #16, revealed that both the chains of IL-12R were consistently expressed. In particular, the CD34 þ CD38 À subset expressed IL-12Rb1 at mean percentage of 89%, range 85-94% (one representative experiment is shown Figure These experiments suggested that AML blasts as well as different AML cell subsets containing leukemic ICs may be targeted by IL-12.
Finally, the expression both the chains of the IL-12R was
À subsets from BM aspirates of six age-matched healthy individuals. This analysis revealed that these sub-population expressed both IL-12Rb1 and IL-12Rb2 chains ( Figure 1c ).
Quick screening of the anti-tumor activity of IL-12 as a new drug against AML: the s.c. in vivo model
The direct anti-tumor activity of IL-12 against the different AML cell subsets was tested in vivo in NSG mice, which represent the most suitable model for efficient engraftment of primary neoplastic cells and ICs. 30, 31 Our first experiment was performed by injecting primary AML cells (Pt #16) s.c. in NSG mice, as this assay is widely used for a quick screening of the anti-tumor activity of a new drug.
First, 8 Â 10 6 AML cells freshly isolated from one patient at diagnosis (Pt #16, 93% CD33 þ IL-12Rb2 þ and 82% CD33 þ IL-12Rb1 þ cells) were injected s.c. into two groups (that are, controls and IL-12 treated) of four NSG mice each.
One week after AML cell injection, all NSG mice developed a palpable nodule at the site of tumor cell inoculation. Seven days later, all hrIL-12-treated mice showed a skin necrotic area close to the nodule. All mice were killed at day 18, as controls showed ruffled furs and systemic illness. Flow cytometric analysis demonstrated that tumors from control mice consisted of 85±4% human CD45 þ cells, of which 10±1.5% were CD34 þ CD38 À , the large majority being CD33 þ CD38 þ ( Figure 2A , upper panels). The latter cells also expressed the CD44 marker (see below). In contrast, tumor masses from hrIL-12-treated mice contained only 7±1.2% CD45 þ cells, and Figure 2A , lower panels). CD34 þ CD38 À cells were undetectable. Morphological analyses revealed that tumors from control NSG mice consisted of small-to-medium-sized blasts ( Figure 2B , subpanel a) with scarce cytoplasm, high nuclear/cytoplasmic ratio and scarce granulocytic differentiation ( Figure 2B , subpanel b). Tumors from controls were endowed with a finely branched microvasculature, as revealed by CD31 immunostaining ( Figure 2B , subpanel c), and rare apoptotic cells ( Figure 2B , subpanel d), as assessed by the terminal deoxynucleotidyl transferase dUTP nick end labeling assay. Treatment with hrIL-12 heavily impaired the viability of most AML blasts ( Figure 2B , subpanel e) and caused necrotic-hemorrhagic breakdown of the tumor masses ( Figure 2B , subpanel f), which were crossed by fragments of microvessel walls ( Figure 2B, subpanel g ) and a few ectatic vessels clogged by granulocytes recruited inside necrotic areas. Moreover, these masses showed more frequent apoptotic events than tumors from controls ( Figure 2B , subpanel h).
IL-12 against pediatric AML cells E Ferretti et al
As IL-12 was found to reduce the angiogenic activity of primary AML cells and to downregulate in vitro expression of IL-6 (see Supplementary Figure 1c) , which represents an autocrine/paracrine factor for AML cell growth, 32 we tested the ability of IL-12 to affect IL-6 expression in vivo. As shown in Figure 2C , tumors from control mice displayed diffuse expression of IL-6 (left panel), whereas such expression was scanty in masses obtained from IL-12-treated mice (right panel).
The above experiments revealed that subcutaneous tumors formed by primary AML cells in control NSG mice contained Thus, we tested whether human cells engrafted in these animals retained the ability to grow in secondary recipients. To this end, CD45 þ cells purified by immunomagnetic beads from tumors of two different control mice were injected s.c. in secondary recipients (n ¼ 2, 1 Â 10 6 cells each). As these mice did not develop a s.c. nodule, they were killed two months and a half after tumor cell inoculation, and the spleen, PB and BM were collected. Flow cytometry analysis revealed that human CD45 þ cells were undetectable in BM and PB, but were found in the spleen (mean ± s.d.%: 45 ± 5%; one representative experiment is shown in Figure 2D , left panel) of both the animals. The latter cells were predominantly composed of CD38 þ leukemia cells with lower proportions of CD34 þ CD38 À cells (mean ± s.d.%: 5 ± 0.5%; Figure 2D , middle panel). Molecular analysis showed that purified CD45 þ cells from the spleen of secondary recipients belonged unambiguously to the original AML clone (Pt #16), as witnessed by the presence of the same polymorphic short tandem repeat loci detected both in primary AML cells at diagnosis and in tumors from control primary recipient ( Figure 2D, right panel) .
We could not assess the tumorigenicity in secondary recipients of residual human CD45 þ cells from IL-12-treated primary recipients due to the poor viability of the few cells remaining following cytokine-induced extensive tissue necrosis.
IL-12 inhibits AML cell growth by acting on different cell fractions in the early phases of in vivo growth 
treated with hrIL-12 and the other five with PBS, following the same schedule reported in the s.c. experiments. Four weeks after AML cell inoculation, mice were killed and PB, spleen and BM cells (obtained from flushing femoral bones) were collected. AML cells from every patient efficiently engrafted in all control and hrIL-12-treated mice, as proved by the presence of at least 1% human CD45 þ cells in the spleen (Figure 3a) . Human cells were absent from PB and BM (human CD45 þ cells o1%) from all IL-12-treated and control mice. Flow cytometric analysis of spleens explanted from control mice revealed that 69-79% of gated mononuclear population expressed the human CD45 marker (see Figure 3a for percentage and 3b for absolute numbers, upper panels). Human CD45 þ cells were comprised of three subsets in the following proportions: 10±3% CD34 þ cells from spleens of both primary and secondary recipients showed the same short tandem repeat loci detected at diagnosis in the original patient sample (Figure 3a , gel on the right).
The finding that primary AML cells did not colonize the BM after 1 month from tumor cell inoculation was quite surprising; thus, additional experiments were performed by prolonging the time of scrutiny of mice injected with primary AML cells. To this end, AML cells from Pt #6 and from four additional AML cell suspensions (Pt #17, #18, #19, or #20) were injected into NSG mice that were killed 2 months later. At this time point, mice treated with PBS or IL-12 started to die of illness. Flow cytometric analysis of PB, spleen and BM harvested from control and IL-12-treated mice revealed similar proportions of leukemia cells in all compartments, including the BM (Figure 3c ). Phenotypic analysis of leukemia cells from spleens, PB and BM revealed that most of them were CD33 þ CD38 þ (mean±s.d.%: controls (CTR) mice ¼ 92±7%; IL-12-treated mice ¼ 95 ± 8%; see Figure 3d ) and expressed the CD44 marker (see below), whereas the CD34 þ CD38 À and CD44 þ CD38
À populations represented only minor fractions in all compartments (CD34 þ CD38 À mean ± s.d.%: CTR mice ¼ 8 ± 3%, IL-12-treated mice ¼ 7 ± 2%; CD44 þ CD38 À mean ± s.d.%: CTR mice ¼ 6 ± 3%, IL-12-treated mice ¼ 6 ± 2%). Purified human CD38 þ cells from BM and spleens of two controls and of two IL-12-treated mice were injected i.v. into secondary NSG recipients (n ¼ 10) in order to evaluate the presence of leukemia ICs. These animals were killed at day 60 after cell inoculation, and spleens, PB and BM were analyzed by flow cytometry. Supplementary Figure 3 ) thus indicating, as previously reported, 17 that the CD38 þ AML cell fraction possesses the ability to give rise to leukemia in NSG mice (not shown).
Mechanisms underlying the lack of IL-12 anti-leukemic activity in late phases of in vivo growth
The intriguing results obtained in our in vivo models prompted us to investigate the potential mechanisms underlying the lack of anti-tumor activity of IL-12 in the late phases of leukemia growth. To this end, we first analyzed IL-12Rb2 expression in human cells found in control mice at day 30, and in both controls and IL-12-treated mice at day 60 after AML cell inoculation. Flow cytometric analysis revealed that: (i) IL-12Rb2 was consistently expressed (IL-12Rb2 þ CD33 þ CD38 þ cells 440%) on leukemia cells from spleens of control mice at day 30 and 60 ( Figures 4A and B upper left panel, respectively) , (ii) IL-12Rb2 was virtually absent (IL-12Rb2
þ cells from PB and BM of controls at day 60 ( Figure 4B , upper middle and right panels) and from spleens, PB and BM of IL-12-treated animals at day 60 ( Figure 4B , lower panels). In addition, molecular analysis by quantitative PCR showed that metastatic cells harvested from BM of control mice did not express IL-12Rb2 mRNA ( Figure 4B , right histogram), thus indicating that the absence of the receptor at the cell surface was due to lack of gene transcription.
Next, we addressed the question of whether IL-12 affected the CD44 þ AML cells in the s.c. and i.v. models chosen on the basis of the following considerations. First, CD44 is a key regulator of trafficking of human CD34 þ stem/progenitor cells to BM; 33 second, CD44 is involved in cancer dissemination; 34 third, CD44 is a key molecule for AML ICs biology; 15 fourth, high levels of the adhesion molecule CD44 on AML cells are essential to generate leukemia after removal of the primary event. Figure 4E) .
Finally, the CD44 þ CD38 þ AML cell fraction that had been engrafted in the spleen on day 30 was not modulated by IL-12 treatment (not shown). Likewise, flow cytometric analysis revealed no significant differences in terms of CD44 surface expression on AML populations present in PB, spleens and BM from controls, and IL-12-treated mice at day 60 (CD44 þ cells mean ± s.d.%: CTR: spleen ¼ 72 ± 5.6%, PB ¼ 62 ± 7.3%, BM ¼ 70±5.6%; IL-12: spleen ¼ 70±6.8%, PB ¼ 64±5.1%, BM ¼ 68.7 ± 2.6%; see Figure 4F ).
These results indicate that from 30 to 60 days after the initial inoculum, AML cells able to spread and expand in NSG mice were constitutively unresponsive to IL-12 and expressed CD44 at high levels. 
Discussion
In this study we have addressed the issue of whether IL-12 may function as anti-tumor agent against pediatric AML cells by targeting AML blasts and/or those populations containing leukemia ICs. Here, we demonstrate for the first time that primary AML cells express functional IL-12R and that IL-12 represents an efficacious anti-tumor agent against pediatric AML in the early phases of in vivo growth.
In vivo experiments were performed using NSG mice, an efficient animal model for engraftment of tumor ICs and bulk tumor cells isolated from patients. 30, 31, 36 In addition, these animals allow to evaluate the anti-tumor activity of human IL-12, which is species-specific on human cells, in the absence of immune response. 18 We chose to use non-irradiated hosts, and engrafted primary AML cells were detected in all NSG animals. A lower efficiency of AML engraftment in immunodeficient animals has been reported in previous studies 15, 16, 30, 33, 37 with the exception of that by Sarry et al. 17 It is conceivable that the high levels of engraftment achieved in our study depend on different variables, including the intrinsic features of the primary leukemia cells injected and/or the use of non-irradiated vs irradiated NSG mice. In this respect, in a recent study performed with NOD/ SCID recipients, radiation was found to induce upregulation of stromal cell-derived factor-1 that, in turn, caused diminished engraftment of acute lymphoblastic leukemia blast. Thus, nonirradiated NSG mice may represent the best assay for preclinical studies using tumor cells freshly isolated from patients, as also suggested by others. (ii) downregulation of IL-6, which acts as an autocrine/paracrine growth factor for AML cells. 32 The ability of IL-12 to inhibit IL-6 was reported in other human tumors, such as multiple myeloma and lung adenocarcinoma, in which, similarly to AML, IL-6 represents an autocrine/paracrine growth factor. 21, 22, 32, 38, 39 In previously published reports 40 and in vitro experiments with primary AML cells here reported, we found that additional proangiogenic factors, such as VEGF-D and especially neuropilin 2, two key molecules involved in lymphangiogenesis and metastasis, were reduced in AML cells treated in vitro with IL-12. By contrast, VEGF-C was found to be upregulated by IL-12. It is of note that neuropilin 2 is a coreceptor for VEGF-C, and forms a complex with VEGFR2 and VEGFR3, necessary for VEGF-C activity. 41 Thus, the upregulation of the pro-angiogenic VEGF-C observed in primary AML cells may represent an attempt of tumor cells to stimulate microvessel formation critically impaired by IL-12. The strong inhibition of angiogenesis operated by IL-12 resulted in tumor cell apoptosis and necrosis. Apoptosis was conceivably an indirect effects of IL-12 on AML cells, as it was not detected in in vitro experiments with primary leukemic cells.
We demonstrated that IL-12 targeted directly in vivo CD45
À subsets, which contain cells with leukemia-initiating properties. 6, 12, 14, 15, 17 After 1 month, s.c. treatment with IL-12 eliminated almost completely all of the above AML cell fractions, thus making their isolation impossible. By contrast, AML cells were successfully purified from control (that is, PBS-treated) mice and found to retain the ability to engraft in secondary recipients. Neoplastic cells grown in primary and secondary recipients derived unambiguously from the original patient sample, as demonstrated by the expression in these cells of the same polymorphic short tandem repeat loci detected in AML cells at diagnosis.
When pediatric AML cells were injected i.v. in NSG mice, two completely different scenarios were observed, depending on the time course. In mice killed after 1 month, AML cells were detected in the spleen, but not in PB or BM, of control mice. All AML cell fractions enriched in blasts or leukemia ICs were found in control mice, whereas they were strongly reduced or absent in IL-12-treated mice. The rare leukemic cells left over in the spleen of IL-12-treated mice did not express IL-12Rb2 mRNA or protein, a finding that predicted their refractoriness to subsequent cycles of IL-12 administration. In contrast, AML cells isolated from the spleen of control mice retained IL-12Rb2 expression.
In mice killed after 2 months from AML cell inoculation, tumor cells expanded in the spleen, PB and BM from either control or IL-12-treated mice. These cells had predominantly a CD33 þ CD38 þ immunophenotype, expressed CD44 and engrafted in secondary recipients, consistent with the recent results of Sarry et al.
17
In order to gain more insight into the mechanisms underlying AML spreading in vivo between 30 and 60 days irrespective of IL-12 treatment, IL-12Rb2 mRNA and protein expression were investigated at day 60 in leukemia cells from the spleen, PB and BM. In both PB and BM, AML cells did not express either IL-12Rb2 mRNA or protein. In contrast, leukemia cells isolated from the spleen of control mice expressed IL-12Rb2, whereas those from the spleen of IL-12-treated mice did not. These results indicated that AML progression and spreading in NSG mice was heralded and accompanied by silencing of the IL-12Rb2 gene, conceivably through epigenetic events. In this respect, we have previously demonstrated that, in chronic B-cell malignancies, IL-12Rb2 gene expression is shut off through methylation of a CpG island in exon 1, thus allowing escape of tumor cells from the direct anti-tumor activity of IL-12. The finding that the spleen of control mice still contained IL-12Rb2 þ AML cells suggests that this anatomical site represents a reservoir of leukemia cells that have not yet undergone metastatic changes and retain sensitivity to IL-12 treatment, as shown by their virtual absence in IL-12-treated mice.
A mechanism that helps to explain the transient inhibition of AML cell growth by IL-12, during the first month, is related to downregulation of CD44 expression in leukemia cells operated by the cytokine. AML progression and spreading to PB and BM in the course of the second month was associated with an increase of CD44 þ leukemic cell subset. CD44 is an adhesion molecule expressed by many types of tumors that was reported to be implicated in accumulation and dissemination of neoplastic cells, enhancing their migration via the afferent lymphatics. 34 Furthermore, it was demonstrated that CD44 is a key regulator of AML ICs function, and is essential for proper homing of AML cells to microenvironmental niches and for maintenance of stemness. 15, 34 In conclusion, our results demonstrate that IL-12 represents an effective anti-AML molecule in the early phases of pediatric AML cell growth in NSG mice, whereas tumor progression is characterized by leukemia cells losing sensitivity to IL-12 due to silencing of the IL-12RB2 gene. In a translational perspective, IL-12 could be used as adjuvant treatment of pediatric AML in the setting of minimal residual disease. Preliminary results from our laboratories indicate that adult AML cells can be targeted by IL-12 similarly to pediatric AML, suggesting that this cytokine may be tested in the clinical setting in a broad range of patients. In this respect, it was demonstrated that IL-12 may have promoting effects on normal hematopoiesis as well as on the engraftment of stem cells, often highly compromised in leukemia patients. 42, 43 In addition, IL-12 could combine direct anti-leukemia activity with activation of anti-tumor immune effector mechanisms. A potential caveat comes from the systemic toxicity of the cytokine, which however appears to be manageable on the basis of recent clinical studies.
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